Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells.

[1]  J. Menéndez,et al.  A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. , 2015, Nuclear medicine and biology.

[2]  M. Minden,et al.  A radiolabeled antibody targeting CD123+ leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML , 2015, Leukemia research reports.

[3]  I. Kerridge,et al.  A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia , 2015, Leukemia & lymphoma.

[4]  M. Minden,et al.  MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells. , 2014, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[5]  M. Weinfeld,et al.  The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates. , 2014, Nuclear medicine and biology.

[6]  H. Ramshaw,et al.  Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC , 2014, Leukemia.

[7]  Jeffrey V. Leyton,et al.  111In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer , 2012, Breast Cancer Research and Treatment.

[8]  J. Dick,et al.  Auger Electron Radioimmunotherapeutic Agent Specific for the CD123+/CD131− Phenotype of the Leukemia Stem Cell Population , 2011, The Journal of Nuclear Medicine.

[9]  A. Kassis,et al.  Targeted Auger Electron Radiotherapy of Malignancies , 2010 .

[10]  M. Minden,et al.  Drug-Resistant AML Cells and Primary AML Specimens Are Killed by 111In-Anti-CD33 Monoclonal Antibodies Modified with Nuclear Localizing Peptide Sequences , 2008, Journal of Nuclear Medicine.

[11]  Manuel Bardiès,et al.  Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons , 2008, Radiation research.

[12]  R. Reilly,et al.  Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. , 2008, Cancer biotherapy & radiopharmaceuticals.

[13]  R. Reilly,et al.  111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer , 2007, Journal of Nuclear Medicine.

[14]  Paul Chen,et al.  Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  R. Reilly,et al.  Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  E. Estey,et al.  Acute Myelogenous Leukemia , 2005 .

[17]  D. Howard,et al.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.

[18]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[19]  S. Gallinger,et al.  Problems of Delivery of Monoclonal Antibodies , 1995, Clinical pharmacokinetics.

[20]  D. Jans.  Nuclear signaling pathways for polypeptide ligands and their membrane receptors? , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  C. Bloomfield,et al.  Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. , 1989, Blood.

[22]  F. E. Bertrand,et al.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy , 2009, Leukemia.

[23]  T. Robak,et al.  Current and emerging therapies for acute myeloid leukemia. , 2009, Clinical therapeutics.

[24]  M. Weinfeld,et al.  Identification of a small molecule inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase. , 2009, Cancer research.

[25]  J. Gamble,et al.  Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist. , 1996, Blood.